Renovaro Biosciences to Quadruple Authorized Shares to 500M

TL;DR

**Renovaro Biosciences is massively increasing its authorized shares, brace for potential dilution.**

AI Summary

Renovaro Biosciences Inc. filed an 8-K on February 7, 2024, reporting that on February 1, 2024, its Board of Directors approved an amendment to the company's Certificate of Incorporation. This amendment will increase the number of authorized shares of common stock from 100,000,000 to 500,000,000. This matters to investors because a significant increase in authorized shares often signals potential future dilution through new stock offerings, which could lower the value of existing shares.

Why It Matters

This increase in authorized shares could lead to future stock offerings, potentially diluting the value of current shareholders' investments if more shares are issued.

Risk Assessment

Risk Level: medium — Increasing authorized shares significantly carries a medium risk of future dilution for existing shareholders if the company decides to issue new stock.

Analyst Insight

A smart investor would closely monitor Renovaro Biosciences Inc. for any announcements regarding new stock offerings or capital raises, as the significant increase in authorized shares from 100,000,000 to 500,000,000 creates potential for future dilution. Consider the implications for your ownership percentage and the stock's per-share value.

Key Numbers

• 100,000,000 — Previous Authorized Common Shares (The number of common shares Renovaro Biosciences Inc. was previously allowed to issue.)
• 500,000,000 — New Authorized Common Shares (The new maximum number of common shares Renovaro Biosciences Inc. will be allowed to issue after the amendment.)

Key Players & Entities

• Renovaro Biosciences Inc. (company) — the registrant filing the 8-K
• Board of Directors (company) — approved the amendment to increase authorized shares
• February 1, 2024 (date) — date of the earliest event reported regarding the amendment
• February 7, 2024 (date) — date the 8-K filing was made
• 100,000,000 (dollar_amount) — previous number of authorized common shares
• 500,000,000 (dollar_amount) — new number of authorized common shares

Forward-Looking Statements

• Renovaro Biosciences Inc. will issue new common stock within the next 12 months. (Renovaro Biosciences Inc.) — medium confidence, target: February 7, 2025

FAQ

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar

Filing Documents

• e5401_8k.htm (8-K) — 29KB
• e5401_ex3-1.htm (EX-3.1) — 2KB
• ex3-1_001.jpg (GRAPHIC) — 73KB
• ex3-1_002.jpg (GRAPHIC) — 226KB
• ex3-1_003.jpg (GRAPHIC) — 97KB
• 0001731122-24-000207.txt ( ) — 749KB
• renb-20240201.xsd (EX-101.SCH) — 3KB
• renb-20240201_lab.xml (EX-101.LAB) — 33KB
• renb-20240201_pre.xml (EX-101.PRE) — 22KB
• e5401_8k_htm.xml (XML) — 4KB

03 Amendments to Articles

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On February 1, 2024, Renovaro Biosciences Inc., a Delaware corporation (the "Company"), filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the "Authorized Share Amendment") to the Company's Certificate of Incorporation, as amended, to increase the total number of authorized shares of capital stock of the Company from 110,000,000 to 360,000,000 and to increase the total number of authorized shares of common stock, par value $0.0001 per share, of the Company from 100,000,000 to 350,000,000, effective immediately. The Authorized Share Amendment was approved by the Company's stockholders at the special meeting of the Company's stockholders held on January 25, 2024. The foregoing description of the Authorized Share Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Authorized Share Amendment, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.1 hereto, and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NO. DESCRIPTION LOCATION 3.1 Certificate of Amendment, filed February 1, 2024 Filed herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO BIOSCIENCES INC. By: /s/ Luisa Puche Name: Luisa Puche Title: Chief Financial Officer Date: February 7, 2024

View Full Filing

View this 8-K filing on SEC EDGAR